Abstract
Fourteen patients with established atrial fibrillation (longer than three months) that was refractory to treatment were studied to compare the clinical and electrophysiological effects of amiodarone and bepridil. All patients initially received bepridil for three weeks (200-600 mg/day), followed by amiodarone for two to three months (100-400 mg/day). Bepridil seemed to be slightly more effective than amiodarone in converting the fibrillation to sinus rhythm (nine of fourteen compared with four of ten). The ventricular response in atrial fibrillation was equally well controlled by bepridil and amiodarone, both at rest and during exercise. Bepridil was associated with the development of ventricular arrhythmias in eight of fourteen patients; two had torsade de pointes, which in one degenerated into fatal ventricular fibrillation. These arrhythmias seemed to be associated with bepridil induced prolongation of the QTc interval. No ventricular arrhythmias were seen during amiodarone treatment. Although bepridil seems to be an effective antiarrhythmic agent for the management of atrial fibrillation, its arrhythmogenic actions make it unsuitable for this purpose.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beaughard M., Ferrier M., Labrid C., Lamar J. C., Leboeuf J., Piris P. Studies on the bradycardia induced by bepridil. Br J Pharmacol. 1982 Feb;75(2):293–300. doi: 10.1111/j.1476-5381.1982.tb08785.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Canicave J. C., Deu J., Jacq J., Paillet R. Un nouvel antiangoreux, le bépridil. Appréciation de son efficacité par l'épreuve d'effort au cours d'un assai à double insu contre placebo. Therapie. 1980 Sep-Oct;35(5):607–612. [PubMed] [Google Scholar]
- Desoutter P., Haiat R. Modification électrocardiographiques induites par le bépridil. Un nouvel inhibiteur calcique. Arch Mal Coeur Vaiss. 1980 Oct;73(10):1237–1238. [PubMed] [Google Scholar]
- DiBianco R., Alpert J., Katz R. J., Spann J., Chesler E., Ferri D. P., Larca L. J., Costello R. B., Gore J. M., Eisenman M. J. Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients. Am J Cardiol. 1984 Jan 1;53(1):35–41. doi: 10.1016/0002-9149(84)90680-5. [DOI] [PubMed] [Google Scholar]
- Kane K. A., Winslow E. Antidysrhythmic and electrophysiological effects of a new antianginal agent, bepridil. J Cardiovasc Pharmacol. 1980;2(2):193–203. doi: 10.1097/00005344-198003000-00010. [DOI] [PubMed] [Google Scholar]
- Labrid C., Grosset A., Dureng G., Mironneau J., Duchene-Marullaz P. Some membrane interactions with bepridil, a new antianginal agent. J Pharmacol Exp Ther. 1979 Dec;211(3):546–554. [PubMed] [Google Scholar]
- Leclercq J. F., Kural S., Valère P. E. Bépridil et torsades de pointes. Arch Mal Coeur Vaiss. 1983 Mar;76(3):341–348. [PubMed] [Google Scholar]
- Rowland E., McKenna W. J., Krikler D. M. Electrophysiologic and antiarrhythmic actions of bepridil. Comparison with verapamil and ajmaline for atrioventricular reentrant tachycardia. Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1513–1519. doi: 10.1016/0002-9149(85)90964-6. [DOI] [PubMed] [Google Scholar]
- Vogel S., Crampton R., Sperelakis N. Blockade of myocardial slow channels by bepridil (CERM-1978). J Pharmacol Exp Ther. 1979 Sep;210(3):378–385. [PubMed] [Google Scholar]